1. Market Research
  2. > Biotechnology
  3. > Medical Biotechnology Market Trends
T-Cell & NK-Cell Engaging Bispecific Antibodies 2019: a business, stakeholder, technology and pipeline analysis

T-Cell & NK-Cell Engaging Bispecific Antibodies 2019: a business, stakeholder, technology and pipeline analysis

  • June 2019
  • 463 pages
  • ID: 5783084
  • Format: PDF
  • By La Merie Publishing


Table of Contents

Search Inside

T-Cell & NK-Cell Engaging Bispecific Antibodies 2019: a business, stakeholder, technology and pipeline analysis

This report provides you with a landscape description and analysis of T-cell and natural killer (NK) cell engaging bispecific antibodies as of June 2019. The report brings you up-to-date information about major pharmaceutical and technology companies active in the field, state of the art and emerging next generation technologies, subject and economic terms of partnering deals and a pipeline analysis of product candidates including clinical experiences.

Analysis is based on the profiles of 56 Big Pharma and technology companies covering company background/history, financial situation, technology overview, partnering activities and pipeline overviw. 38 different technologies to create bispecific T-cell and NK cell engaging antibodies are profiled in depth. Pipeline analysis is based on the profiles of 90 drug candidates in development. Sources of information are 237 scientific references. Non-scientific sources of information, such as press releases, annual reports and presentations, are disclosed within the text with an embedded hyperlink leading to the online source of information.

Immunotherapy of cancer with T-cells oder NK cells is an area of great interest for the biopharmaceutical industry. Chimeric antigen receptor (CAR) engineered T-cell or NK cells represent one treatment modality under clinical evaluation, but the majority of Big Pharma prefers the engagement of T-cells or NK cells by recombinant monoclonal antibodies as off-the-shelf products. As only a few major pharmaceutical companies have clinically validated in-house bispecific antibody technology, partnering with technology providing companies is of great importance.

Within three years, the number of clinical stage T-cell and NK cell engagers has more than doubled and further product candidates will enter clinical evaluation in the near future.

This report will show you that there are plenty of opportunities for players in the field, including major pharmas, technology providers and investors.

This report will inform you about Big Pharma’s

  • In-house technologies and product candidates;
  • Technology and target in-licensing preferences;
  • Preferred product profile (half-life, safety features, effector cell type, and target type);
  • Economic deal terms.
38 technology companies with T-cell and NK cell engaging bispecific antibody technologies are analyzed regarding their

  • In house established technologies to redirect T-cells and NK cells or engage cotimulatory molecules;
  • Emerging technologies to generate bispecifics with longer half-life, greater safety, higher efficacy and to target intracellular targets via peptide MHC complexes;
  • In-house product candidates in development (technology used, construct, target, indication, R&D phase).
The profiles of 58 clinical stage and 25 non-clinical development stage T-cell and NK cell engaging bispecific antibodies form the basis of

  • Competitor analysis for a given target
  • Description of popular targets and bispecific antibody technologies
  • Discussion of product candidates from emerging next generation technologies
  • Learnin from clinical experience in hematologic and solid tumor indications.
So far, the attrition rate of T-cell and NK cell engaging antibodies is relatively low (12%). This report identified the terminated bispecific T-cell engager projects and the reasons for discontinuation.

This report also analyzes the financial „maturity“ of technology companies and their specific sources of funding. Overall, raising money for bispecific T-cell and NK cell engagers is no fundamental problem

What will you find in the report?

  • Profiles of 56 companies active in the field;
  • Comprehensive description and analysis of 38 established or emerging T-cell or NK-cell engaging antibody technologies;
  • Profiles of one approved, 89 T-cell or NK-cell engaging bispecific antibodies in all phases of development, and analysis of eight discontinued bispecific T-cell engagers;
  • Technology selection and preferences of major pharma;
  • Key characteristics of technologies with clinical stage drug candidates;
  • Emerging alternative bi- and trispecific formats;
  • Target selection and competition of drug candidates;
  • Competitive evaluation of clinical experience with bispecific T-cell and NK cell engagers;
  • Economic terms of collaboration and licensing deals;
  • Sources of financing.
Who will benefit from the report?

  • Venture capital, private equity and investment managers;
  • Financial analysts;
  • CFO;
  • Business development and licensing (BDL) specialists;
  • Marketing managers;
  • CEO, COO and managing directors;
  • Corporate strategy analysts and managers;
  • Chief Technology Officer;
  • R&D Management in Oncology;
  • R&D Portfolio, Technology and Strategy Management;
  • Cell technology and manufacturing specialists;
  • Clinical and preclinical development specialists.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
Granulomatosis with Polyangiitis (Wegener Polyangiitis) - Pipeline Review, H1 2019

Granulomatosis with Polyangiitis (Wegener Polyangiitis) - Pipeline Review, H1 2019

  • $ 2000
  • May 2019

Granulomatosis with Polyangiitis (Wegener Polyangiitis) - Pipeline Review, H1 2019SummaryGlobal Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Granulomatosis with Polyangiitis ...

Encephalomyelitis Global Clinical Trials Review, H1, 2019

Encephalomyelitis Global Clinical Trials Review, H1, 2019

  • $ 2500
  • May 2019

Encephalomyelitis Global Clinical Trials Review, H1, 2019SummaryGlobalData’s clinical trial report, “Encephalomyelitis Global Clinical Trials Review, H1, 2019" provides an overview of Encephalomyelitis ...

C-X-C Chemokine Receptor Type 2 - Pipeline Review, H1 2019

C-X-C Chemokine Receptor Type 2 - Pipeline Review, H1 2019

  • $ 3500
  • May 2019

C-X-C Chemokine Receptor Type 2 - Pipeline Review, H1 2019SummaryC-X-C Chemokine Receptor Type 2 (CDw128b or GRO/MGSA Receptor or High Affinity Interleukin 8 Receptor B or IL8 Receptor Type 2 or CD182 ...


Reportlinker.com © Copyright 2019. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on